British Journal of Renal Medicine - 2003


Comment: Expert patients – a benefit to themselves and the NHS
John Bradley
pp 4-4
During the course of their illness, patients with renal failure develop a wealth of knowledge and expertise, which, in some areas, may surpass that of the healthcare professionals caring for them. As Drs Winearls and Pugh make clear, nephrologists can learn a lot from their patients. The knowledge and understanding that renal patients have about their own illness is an important determinant of their long-term health and survival.
Staying one step ahead – one patient’s dialysis experience
Christopher G Winearls and Christopher W Pugh
pp 6-9
In 2002, Belding Scribner and Wilhelm Kolff were awarded the Lasker Award for Clinical Medical Research in recognition of their pioneering work, which showed the potential of haemodialysis to save and extend the lives of patients with end-stage renal failure (ESRF). Although the success of this technical advance owes much to them, the courage of the early patients submitted to this treatment should not be forgotten.
Specialism within a specialty: diabetes and dialysis
Gillian Atherton
pp 10-11
Diabetes is the leading cause of end-stage renal failure (ESRF) in the Western world. Approximately 40% of patients with Type 1 diabetes and between 5–40% with Type 2 diabetes will develop diabetic nephropathy that can lead to ESRF.
What I tell my patients about kidney transplantation
Stephen J Wigmore and John LR Forsythe
pp 13-16
Kidney transplantation is a successful long-term treatment for kidney failure. It offers greater freedom and improved health benefits compared with the other forms of treatment for kidney failure, which involve dialysis.
Total dose iron infusion: testing a Sunday service
George Peebles and Pearl Pai
pp 17-17
Cost pressures, limited space and growing waiting lists underpin the need for more efficient and effective working practices. At Sunderland Royal Hospital, prescribing and administration of intravenous (IV) iron was one practice we needed to improve. The successful management of anaemia in renal failure requires careful management of iron status.
Support for bringing funding back into secondary care
David V Hamilton
pp 18-19
In the last issue, Colin Brown raised the problem of shared-care funding. Part of this problem is that renal expertise is concentrated in secondary care, with most GPs having only one or two renal patients on their list. Haemodialysis patients attend the renal unit two to three times a week, depending on their residual renal function, haemodialysis facilities and, to some extent, their own wishes.
Medicines management for haemodialysis outpatients
Alexandra Fotherby and Soraya Dhillon
pp 20-23
Haemodialysis patients are often seen by different nephrology clinicians, resulting in multiple drug therapies and frequent changes to their medication. As a consequence, there is a need to review the pharmaceutical care processes for renal patients in accordance with The NHS Plan and in anticipation of the Renal National Service Framework.
Multicultural culinary challenges in renal replacement therapy
Abi Mogridge
pp 24-26
The 1991 census showed that ethnic minorities constitute 5.5% of the UK population. About half of these are of south Asian origin, while the second largest group is of Black African/African–Caribbean origin (0.9% of the population). Their geographical distribution is uneven, with most living in Greater London. East London comprises 11.2% Bangladeshi, closely followed by Black African/African–Caribbean (8.1% and 7.4% respectively).
Dr Donal O’Donoghue – new co-chair of renal services ERG

pp 27-27
Health Minister Rosie Winterton announced Dr Donal O’Donoghue as the new co-chair of the renal services external reference group (ERG). The announcement came as part of a fact-finding visit to Hope Hospital in Salford, during which Rosie Winterton heard from staff and patients about the Greater Manchester Renal Managed Clinical Network.

The British Journal of Renal Medicine was previously supported by Baxter Healthcare from 2011 to 2013, by Sandoz in 2011, by Shire Pharmaceuticals from 2006 to 2011, by Ortho Biotech and Shire Pharmaceuticals in 2005, by Ortho Biotech from 2000 to 2005 and by Janssen Cilag from 1996 to 2000.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly, the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title British Journal of Renal Medicine is the property of Hayward Group Ltd and, together with the content, is bound by copyright. Copyright © 2017 Hayward Group Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1365-5604 (Print)  ISSN 2045-7839 (Online)